Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

When AbbVie inked its $63 billion Allergan deal, one fear above all motivated the deal: Biosimilars to megablockbuster Humira, due stateside in 2023. But Allergan's best-selling Botox and other promising drugs may not be enough. What could help? Hiving off assets—or so figures one analyst who's called for Allergan selloffs before.